Preliminary Application of the Novel Biomarker TANS01 in Cardiovascular Risk Assessment among Individuals with Phlegm-dampness Constitution

doi:10.12114/j.issn.1007-9572.2025.0449

Chinese General Practice ›› 2026, Vol. 29 ›› Issue (27): 3924-3930.DOI: 10.12114/j.issn.1007-9572.2025.0449

• Article • Previous Articles Next Articles

Preliminary Application of the Novel Biomarker TANS01 in Cardiovascular Risk Assessment among Individuals with Phlegm-dampness Constitution

1. Department of Cardiology, Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China
2. Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
3. College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
4. Incubation and Translation Department, National Innovation Center for Modern Chinese Medicine, Tianjin 300392, China

Received:2025-10-21 Revised:2026-03-17 Published:2026-09-20 Online:2026-08-11
Contact: LU Meijuan

新型指标TANS01在痰湿体质人群心血管风险评估中的初步应用研究

1．300250　天津市，天津中医药大学第二附属医院心血管内科
2．301617　天津市，天津中医药大学研究生院
3．301617　天津市，天津中医药大学中医学院
4．300392　天津市，国家现代中药创新中心孵化转化部

通讯作者: 路美娟
作者简介:
作者贡献：
郭俊池提出主要研究目标，负责研究构思与设计、研究实施、数据收集与整理、统计学分析及图表绘制，撰写论文初稿；张明妍参与数据整理、变量定义及表格绘制，负责中英文校对；秦广宁参与论文修订，并对"湿浊痰饮类病"理论相关内容进行补充完善；徐强负责模型设计与统计学分析指导，参与论文修订；路美娟负责研究总体设计与学术指导，对论文进行质量控制与审校，对文章整体负责。
基金资助:
国家自然科学基金面上项目(82374619，82374195); 天津市卫健委中医中西医结合科研课题(2023027)

Abstract

Abstract:

Background

Cardiovascular disease (CVD) is one of the leading causes of death worldwide, and its incidence continues to rise with the increasing prevalence of metabolic disorders. The phlegm-dampness constitution is considered a potential risk factor for CVD; however, its association with CVD has not been sufficiently validated in epidemiological studies.

Objective

This study aimed to construct a novel variable, TANS01, to characterize the phlegm-dampness constitution and to investigate its association with the risk of CVD, thereby evaluating the cardiovascular risk among individuals with phlegm-dampness constitution.

Methods

We included 15 279 participants from seven survey cycles (2003-2016) of the National Health and Nutrition Examination Survey (NHANES) database. A binary indicator, TANS01, was constructed to represent the phlegm-dampness constitution. Epidemiological analysis was conducted to investigate the potential relationship between the novel TANS01 indicator and CVD incidence. Univariate and multivariate logistic regression analyses were employed to explore the association between TANS01 and various cardiovascular outcome variables.

Results

Based on the TANS01 classification, participants were divided into a phlegm-dampness constitution group (n=6 437) and a non-phlegm-dampness constitution group (n=8 842). Statistically significant differences (P<0.05) were observed between the two groups regarding age, age groups, sex, smoking, alcohol consumption, hypertension, overweight, dyslipidemia, dietary preferences, lack of exercise, heart failure, BMI, white blood cell count (WBC), red blood cell count (RBC), hemoglobin (Hb), glycated hemoglobin (HbA_1c), fasting plasma glucose (FPG), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), uric acid (UA), and creatinine (Cr). Univariate Logistic regression analysis indicated that TANS01 was a risk factor for heart failure (OR=2.67, 95%CI=2.04-3.49, P<0.001), coronary heart disease (OR=2.04, 95%CI=1.66-2.51, P<0.001), and angina pectoris (OR=2.29, 95%CI=1.72-3.03, P<0.001). The association remained robust after adjusting for confounding factors (age, sex, smoking, and alcohol consumption) in the multivariate Logistic regression analysis. Subgroup analysis revealed that TANS01 was a risk factor for heart failure across different subgroups defined by sex, age, smoking, alcohol consumption, diabetes, and hypertension status (P<0.05), with no statistically significant difference in predictive efficacy among subgroups (P_interaction>0.05). Similarly, TANS01 was a risk factor for coronary heart disease and angina pectoris across subgroups of sex, age, smoking, and alcohol consumption (P<0.05); however, the predictive value of TANS01 for coronary heart disease and angina pectoris was not statistically significant in patients with diabetes and hypertension (P>0.05).

Conclusion

The findings of this study demonstrate a significant association between TANS01 and the risk of CVD, including heart failure, coronary heart disease, and angina pectoris. This provides epidemiological evidence supporting the phlegm-dampness constitution as a significant risk factor for CVD. Future research should further explore the underlying mechanisms of the phlegm-dampness constitution in CVD and promote its application in clinical prevention.

Key words: Cardiovascular diseases, Heart failure, Coronary heart disease, Phlegm-damp constitution, Similar diseases and syndromes of damp-turbidity-phlegm-rheum

摘要：

背景

心血管疾病（CVD）是全球主要的死亡原因之一，随着代谢性疾病的增加，其发病率呈上升趋势。痰湿体质是CVD的潜在风险因素，但其与CVD之间的关系尚未得到充分的流行病学验证。

目的

本研究构建TANS01变量表征痰湿体质并探究与CVD的风险关系，评估痰湿体质在人群中的CVD风险。

方法

纳入美国国家健康与营养调查（NHANES）数据库2003—2016年的7个调查周期的15 279例参与者，构建二分类指标TANS01以表征痰湿体质，并通过流行病学分析探究新型指标TANS01与CVD发病率的潜在关系，采用单因素或多因素Logistic回归分析探究TANS01与各个心血管结局变量的关系。

结果

根据TANS01指标分类将研究对象分为痰湿体质人群6 437例，非痰湿体质人群8 842例。非痰湿体质人群与痰湿体质人群比较，年龄、年龄分组、性别、吸烟、饮酒、高血压、超重、血脂异常、饮食偏嗜、运动偏少、心力衰竭、BMI、白细胞计数（WBC）、红细胞计数（RBC）、血红蛋白（Hb）、糖化血红蛋白（HbA_1c）、空腹血糖（FPG）、低密度脂蛋白胆固醇（LDL-C）、甘油三酯（TG）、天冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）、尿酸（UA）、肌酐（Cr）比较，差异有统计学意义（P<0.05）。单因素Logistic回归分析结果显示，TANS01是心力衰竭（OR=2.67，95%CI=2.04~3.49，P<0.001）、冠心病（OR=2.04，95%CI=1.66~2.51，P<0.001）和心绞痛（OR=2.29，95%CI=1.72~3.03，P<0.001）的危险因素，多因素Logistic回归分析结果显示，在控制混杂因素（年龄、性别、吸烟和饮酒）后关联依然稳健。亚组分析结果显示，TANS01在不同性别、年龄、吸烟、饮酒、糖尿病、高血压患病情况中均为心力衰竭的危险因素（P<0.05），在不同亚组间预测效能差异无统计学意义（P_交互>0.05）；TANS01在不同性别、年龄、吸烟、饮酒情况中均为冠心病及心绞痛的危险因素（P<0.05），在糖尿病和高血压患者中TANS01对冠心病及心绞痛预测价值无统计学意义（P>0.05）。

结论

本研究结果表明TANS01与心力衰竭、冠心病和心绞痛等CVD的风险显著相关，为痰湿体质与CVD的关系提供了流行病学证据，支持痰湿体质作为CVD的重要风险因素。未来研究应进一步探索痰湿体质对CVD的作用机制，并推动其在临床预防中的应用。

关键词: 心血管疾病, 心力衰竭, 冠心病, 痰湿体质, 湿浊痰饮类病

GUO Junchi,ZHANG Mingyan,QIN Guangning, et al. Preliminary Application of the Novel Biomarker TANS01 in Cardiovascular Risk Assessment among Individuals with Phlegm-dampness Constitution[J]. Chinese General Practice, 2026, 29(27): 3924-3930. DOI: 10.12114/j.issn.1007-9572.2025.0449.
郭俊池,张明妍,秦广宁等. 新型指标TANS01在痰湿体质人群心血管风险评估中的初步应用研究[J]. 中国全科医学, 2026, 29(27): 3924-3930. DOI: 10.12114/j.issn.1007-9572.2025.0449.

Figures/Tables 4

References 31

[1]	Tian Y H, Zhang J, Huang C Y, et al. Ambient polycyclic aromatic hydrocarbons and cardiovascular disease in China[J]. J Hazard Mater, 2025, 491: 137948. DOI: 10.1016/j.jhazmat.2025.137948.
[2]	Cao X, Tian Y X, Zhao Z P, et al. Disparities in high fasting plasma glucose-related cardiovascular disease burden in China[J]. Nat Commun, 2024, 15(1): 8817. DOI: 10.1038/s41467-024-53236-y.
[3]	Banach M, Surma S, Guzik T J, et al. Upfront lipid-lowering combination therapy in high cardiovascular risk patients: a route to effective atherosclerotic cardiovascular disease prevention[J]. Cardiovasc Res, 2025, 121(6): 851-859. DOI: 10.1093/cvr/cvaf045.
[4]	Li S, Liu H H, Zhang Y, et al. Prognostic role of lipoprotein(a) in atherosclerotic cardiovascular disease risk from a perspective on current risk stratification[J]. MedComm, 2024, 5(11): e773. DOI: 10.1002/mco2.773.
[5]	朱晶晶，张扬，龚小会, 等. 基于人工智能算法与中医体质类型的老年糖尿病患者合并心血管疾病预测模型[J]. 上海中医药杂志, 2025, 59(3): 1-6. DOI: 10.16305/j.1007-1334.2025.z20240801001.
[6]	施甜. 青少年中医体质类型与心血管危险因素的相关性及其防治的研究[J]. 心血管病防治知识, 2024, 14(11): 15-17, 21.
[7]	李霄，金鑫瑶，吕玲, 等. 张伯礼"湿浊痰饮类病证治"学术思想撮要[J]. 中医杂志, 2022, 63(17): 1620-1624. DOI: 10.13288/j.11-2166/r.2022.17.005.
[8]	秦广宁，金鑫瑶，刘耀远, 等. 基于张伯礼"湿浊痰饮类病"学说浅析射血分数保留的心力衰竭治疗策略[J]. 中医杂志, 2024, 65(1): 35-38, 43. DOI: 10.13288/j.11-2166/r.2024.01.007.
[9]	马艳苗，刘明燃，宋博, 等. 中医气象-地理-体质学说述略[J]. 中华中医药杂志, 2024, 39(9): 4572-4576.
[10]	Edwards B J, Zhang X T. Effect of fractures on overall survival in cancer patients: the NHANES database[J]. J Clin Oncol, 2019, 37(15_suppl): e23024. DOI: 10.1200/jco.2019.37.15_suppl.e23024.
[11]	刘兴，王琦，李炜, 等. 痰湿体质知识图谱构建研究初探[J]. 北京中医药大学学报, 2022, 45(9): 949-955.
[12]	罗悦，周娟. 基于随机森林的中医痰湿体质预测模型研究[J]. 世界科学技术-中医药现代化, 2024, 26(7): 1906-1915. DOI: 10.11842/wst.20230605004.
[13]	王怀玉，赵彤，王济, 等. 中医药跨学科交叉研究模式探讨——以痰湿体质血脂异常未病状态的客观表征为例[J]. 中医杂志, 2024, 65(6): 553-556. DOI: 10.13288/j.11-2166/r.2024.06.001.
[14]	Cao Y X, Yu Y. Associations between cholesterol intake, food sources and cardiovascular disease in Chinese residents[J]. Nutrients, 2024, 16(5): 716. DOI: 10.3390/nu16050716.
[15]	Azarmanesh D, Man K W, Zheng P X, et al. The association of the Lifestyle Inflammatory Score (LIS) with depression among adults in the United States: National Health and Nutrition Examination Survey (NHANES) 2007-2010, 2015-2018, 2021-2023[J]. J Affect Disord, 2026, 393(Pt B): 120401. DOI: 10.1016/j.jad.2025.120401.
[16]	Jiang Z P, Park B Y. Association of physical activity, sedentary behavior, and sleep duration with major depressive disorder: a cross-sectional and Mendelian randomization study[J]. J Affect Disord, 2026, 392: 120309. DOI: 10.1016/j.jad.2025.120309.
[17]	Global Burden of Disease 2023 Risk Factors Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023[J]. J Am Coll Cardiol, 2025, 86(22): 2167-2243. DOI: 10.1016/j.jacc.2025.08.015.
[18]	王琦. 中医体质学对共病诊疗的理论创新与实践[J]. 北京中医药大学学报, 2025, 48(11): 1481-1486. DOI: 10.3969/j.issn.1006-2157.2025.11.001.
[19]	Li L R, Li T X, Liang X, et al. A decrease in Flavonifractor plautii and its product, phytosphingosine, predisposes individuals with phlegm-dampness constitution to metabolic disorders[J]. Cell Discov, 2025, 11(1): 25. DOI: 10.1038/s41421-025-00789-x.
[20]	Larsen T S, Jansen K M. Impact of obesity-related inflammation on cardiac metabolism and function[J]. J Lipid Atheroscler, 2021, 10(1): 8-23. DOI: 10.12997/jla.2021.10.1.8.
[21]	Zhang Y, Wei Y, Han X J, et al. Faecalibacterium prausnitzii prevents age-related heart failure by suppressing ferroptosis in cardiomyocytes through butyrate-mediated LCN2 regulation[J]. Gut Microbes, 2025, 17(1): 2505119. DOI: 10.1080/19490976.2025.2505119.
[22]	曹凤娇，易文明，吴梦玮, 等. 基于痰湿体质的高尿酸血症防治策略研究进展[J]. 中国医药科学, 2025, 15(13): 42-45. DOI: 10.20116/j.issn2095-0616.2025.13.08.
[23]	朱倩倩，王澜，姜楠, 等. 基于深度学习的痰湿体质高血压舌象识别[J]. 中国医学物理学杂志, 2025, 42(4): 534-541. DOI: 10.3969/j.issn.1005-202X.2025.04.016.
[24]	郭俊池，张明妍，徐强, 等. "湿浊痰饮类病"理论整合转录组学与孟德尔随机化构建痰湿体质人群心力衰竭风险中的核心基因模型[J]. 天津中医药大学学报, 2025, 44(8): 673-678. DOI: 10.11656/j.issn.1673-9043.2025.08.01.
[25]	Wang J, Wang Q, Li L R, et al. Phlegm-dampness constitution: genomics, susceptibility, adjustment and treatment with traditional Chinese medicine[J]. Am J Chin Med, 2013, 41(2): 253-262. DOI: 10.1142/S0192415X13500183.
[26]	Shin J, Li T X, Zhu L H, et al. Obese individuals with and without phlegm-dampness constitution show different gut microbial composition associated with risk of metabolic disorders[J]. Front Cell Infect Microbiol, 2022, 12: 859708. DOI: 10.3389/fcimb.2022.859708.
[27]	You Z Y, Lu J H, Xu Y F, et al. Metabolic markers of tongue coating in healthy people with phlegm dampness constitution and damp-heat constitution[J]. Discover Life, 2024, 54(1): 28. DOI: 10.1007/s11084-024-09674-1.
[28]	Heineke J, Kempf T, Kraft T, et al. Downregulation of cytoskeletal muscle LIM protein by nitric oxide: impact on cardiac myocyte hypertrophy[J]. Circulation, 2003, 107(10): 1424-1432. DOI: 10.1161/01.cir.0000055319.94801.fc.
[29]	Suematsu N, Tsutsui H, Wen J, et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes[J]. Circulation, 2003, 107(10): 1418-1423. DOI: 10.1161/01.cir.0000055318.09997.1f.
[30]	Lee J, Lee S, Zhang H R, et al. Interaction of IL-6 and TNF-α contributes to endothelial dysfunction in type 2 diabetic mouse hearts[J]. PLoS One, 2017, 12(11): e0187189. DOI: 10.1371/journal.pone.0187189.
[31]	吕蕊婷，艾彦伶，杨忠奇, 等. "治未病"中药新药研发与中药创新[J]. 中国中药杂志, 2025, 50(13): 3589-3595. DOI: 10.19540/j.cnki.cjcmm.20250310.603.

特征类别	NHANES模块	变量名称
超重	Examination data	BMXBMI（BMI）
血脂异常	Laboratory data	LBDLDL（LDL-C）、LBXTR（TG）
代谢紊乱	Laboratory data	LBXGLU（FPG）、LBXGH（HbA_1c）
饮食偏嗜	Dietary data	DR1ITFAT
运动量偏少	Physical Activity Questionnaire	PAD020/PAQ635

特征类别	NHANES模块	变量名称
超重	Examination data	BMXBMI（BMI）
血脂异常	Laboratory data	LBDLDL（LDL-C）、LBXTR（TG）
代谢紊乱	Laboratory data	LBXGLU（FPG）、LBXGH（HbA_1c）
饮食偏嗜	Dietary data	DR1ITFAT
运动量偏少	Physical Activity Questionnaire	PAD020/PAQ635

组别	例数	年龄（±s，岁）	年龄[例（%）]		性别（男/女）	吸烟[例（%）]	饮酒[例（%）]	高血压[例（%）]	超重[例（%）]	血脂异常[例（%）]
组别	例数	年龄（±s，岁）	≥60岁	<60岁	性别（男/女）	吸烟[例（%）]	饮酒[例（%）]	高血压[例（%）]	超重[例（%）]	血脂异常[例（%）]
非痰湿体质人群	6 437	43.1±17.1	1 649（19.4）	4 788（80.6）	2 857/3 580	2 822（44.8）	4 693（78.0）	1 556（21.4）	2 685（40.8）	1 278（19.8）
痰湿体质人群	8 842	50.9±15.9	3 501（31.4）	5 341（68.6）	4 667/4 175	4 222（48.1）	6 171（74.6）	3 944（41.5）	8 056（91.8）	6 047（70.0）
χ²（t）值		21.176^a	325.702		170.420	16.844	23.888	694.550	4 592.400	3 819.300
P值		<0.001	<0.001		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
组别	血糖代谢紊乱[例（%）]	饮食偏嗜[例（%）]	运动偏少[例（%）]	心力衰竭[例（%）]	冠心病[例（%）]	心绞痛[例（%）]	BMI（±s，kg/m²）	WBC（±s，×10⁹/L）	RBC（±s，×10¹²/L）
非痰湿体质人群	1 752（23.3）	440（6.3）	3 625（58.8）	119（1.3）	175（2.2）	98（1.3）	25.58±5.62	6.54±2.27	4.64±0.48
痰湿体质人群	7 118（77.4）	1 790（19.3）	7 725（88.8）	381（3.5）	446（4.4）	293（2.9）	31.45±6.53	7.07±2.29	4.79±0.48
χ²（t）值	4 434.000	548.940	1 835.000	70.890	55.298	46.202	42.889^a	12.438^a	16.238^a
P值	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
组别	Hb（±s，g/dL）	HbA_1c （±s，%）	FPG（±s，mg/dL）	LDL-C（±s，mg/dL）	TG（±s，mg/dL）	AST（±s，U/L）	ALT（±s，U/L）	UA（±s，μmol/L）	Cr（±s，mg/dL）
非痰湿体质人群	14.22±1.45	5.30±0.57	95.51±17.47	104.29±29.87	97.37±73.81	24.49±14.41	22.64±15.01	299.87±74.88	0.86±0.38
痰湿体质人群	14.52±1.50	5.82±1.09	113.0±36.16	123.91±36.73	158.36±125.50	26.50±21.43	28.21±22.26	345.80±83.03	0.91±0.39
χ²（t）值	10.499^a	31.605^a	30.490^a	31.992^a	29.265^a	6.768^a	17.576^a	25.774^a	6.779^a
P值	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

组别	例数	年龄（±s，岁）	年龄[例（%）]		性别（男/女）	吸烟[例（%）]	饮酒[例（%）]	高血压[例（%）]	超重[例（%）]	血脂异常[例（%）]
组别	例数	年龄（±s，岁）	≥60岁	<60岁	性别（男/女）	吸烟[例（%）]	饮酒[例（%）]	高血压[例（%）]	超重[例（%）]	血脂异常[例（%）]
非痰湿体质人群	6 437	43.1±17.1	1 649（19.4）	4 788（80.6）	2 857/3 580	2 822（44.8）	4 693（78.0）	1 556（21.4）	2 685（40.8）	1 278（19.8）
痰湿体质人群	8 842	50.9±15.9	3 501（31.4）	5 341（68.6）	4 667/4 175	4 222（48.1）	6 171（74.6）	3 944（41.5）	8 056（91.8）	6 047（70.0）
χ²（t）值		21.176^a	325.702		170.420	16.844	23.888	694.550	4 592.400	3 819.300
P值		<0.001	<0.001		<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
组别	血糖代谢紊乱[例（%）]	饮食偏嗜[例（%）]	运动偏少[例（%）]	心力衰竭[例（%）]	冠心病[例（%）]	心绞痛[例（%）]	BMI（±s，kg/m²）	WBC（±s，×10⁹/L）	RBC（±s，×10¹²/L）
非痰湿体质人群	1 752（23.3）	440（6.3）	3 625（58.8）	119（1.3）	175（2.2）	98（1.3）	25.58±5.62	6.54±2.27	4.64±0.48
痰湿体质人群	7 118（77.4）	1 790（19.3）	7 725（88.8）	381（3.5）	446（4.4）	293（2.9）	31.45±6.53	7.07±2.29	4.79±0.48
χ²（t）值	4 434.000	548.940	1 835.000	70.890	55.298	46.202	42.889^a	12.438^a	16.238^a
P值	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001
组别	Hb（±s，g/dL）	HbA_1c （±s，%）	FPG（±s，mg/dL）	LDL-C（±s，mg/dL）	TG（±s，mg/dL）	AST（±s，U/L）	ALT（±s，U/L）	UA（±s，μmol/L）	Cr（±s，mg/dL）
非痰湿体质人群	14.22±1.45	5.30±0.57	95.51±17.47	104.29±29.87	97.37±73.81	24.49±14.41	22.64±15.01	299.87±74.88	0.86±0.38
痰湿体质人群	14.52±1.50	5.82±1.09	113.0±36.16	123.91±36.73	158.36±125.50	26.50±21.43	28.21±22.26	345.80±83.03	0.91±0.39
χ²（t）值	10.499^a	31.605^a	30.490^a	31.992^a	29.265^a	6.768^a	17.576^a	25.774^a	6.779^a
P值	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001	<0.001

因变量	模型1		模型2		模型3
因变量	OR（95%CI）	P值	OR（95%CI）	P值	OR（95%CI）	P值
心力衰竭	2.67（2.04~3.49）	<0.05	1.87（1.43~2.44）	<0.05	1.85（1.42~2.41）	<0.05
冠心病	2.04（1.66~2.51）	<0.05	1.37（1.10~1.70）	<0.05	1.36（1.09~1.69）	<0.05
心绞痛	2.29（1.72~3.03）	<0.05	1.59（1.20~2.11）	<0.05	1.57（1.18~2.09）	<0.05
因变量	模型4		模型5		模型6
因变量	OR（95%CI）	P值	OR（95%CI）	P值	OR（95%CI）	P值
心力衰竭	1.58（1.21~2.06）	<0.05	1.35（1.03~1.78）	<0.05	1.23（0.93~1.63）	0.14
冠心病	1.18（0.94~1.48）	0.15	1.06（0.84~1.33）	0.62	1.02（0.83~1.28）	0.79
心绞痛	1.36（1.01~1.83）	<0.05	1.19（0.88~1.61）	0.24	1.12（0.83~1.53）	0.45

Preliminary Application of the Novel Biomarker TANS01 in Cardiovascular Risk Assessment among Individuals with Phlegm-dampness Constitution

新型指标TANS01在痰湿体质人群心血管风险评估中的初步应用研究

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 31

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	WANG Wei, YU Fei, YAN Xiaohong. Application and Mechanisms of Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure with Different Etiologies: Evidence from Ischemic and Non-ischemic Heart Failure [J]. Chinese General Practice, 2026, 29(27): 3976-3984.
[2]	ZHAO Yuanyuan, LIU Pulin, DAI Juan, ZHANG Gang, ZHANG Wei, ZHANG Xiaoxia, DENG Qing, YAN Yaqiong. Association Study between Chinese Visceral Adiposity Index and Risk of All-cause and Cause-specific Mortality in the Elderly [J]. Chinese General Practice, 2026, 29(26): 3781-3787.
[3]	YANG Rui, LIAO Xiaoyang, HUANG Chuanying, YANG Ziyu, SHEN Can, JIA Yu, LIU Lidi, YANG Rong. Interpretation of the 2024 British and Irish Hypertension Society Position Statement: Investigation and Management of Hypertension in Young People [J]. Chinese General Practice, 2026, 29(26): 3726-3732.
[4]	ZHAO Yiru, HAO Xinyu, ZHAO Lei, ZHANG Caihui, WANG Zhaoxia, ZHANG Yueying. Summary of the Best Evidence for the Management of Diuretic Resistance in Patients with Heart Failure [J]. Chinese General Practice, 2026, 29(25): 3694-3703.
[5]	LI Jia, HE Jun, ZHU Jinmei, LIU Fuming, WU Yuan, DING Yuquan, QIAN Hua, XU Xinyu. Effects of Low-volume High-intensity Interval Training Combined with Virtual Reality Technology on Cardiac Rehabilitation in Patients with Coronary Heart Disease [J]. Chinese General Practice, 2026, 29(25): 3640-3649.
[6]	LI Xueni, LIU Gejing, LIU Yongming. Efficacy and Safety of Semaglutide in Patients with Heart Failure: a Meta-Analysis [J]. Chinese General Practice, 2026, 29(24): 3509-3519.
[7]	SUN Qinyu, YANG Tianxiao, DENG Yifan, FANG Zhen, JI Jun, HE Shenghu, ZHANG Jing. Analysis of the Correlation between Different Surrogate Indicators of Insulin Resistance and the Occurrence of MACEs after PCI in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease and Coronary Heart Disease [J]. Chinese General Practice, 2026, 29(22): 3146-3153.
[8]	LI Shilong, WANG He, ZHOU Xiaoyu, FU Lei, ZHAO Zhuo, HUA Chengjun, SI Chunying. Advances in the Study of Cardiac Macrophages in Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2026, 29(15): 2084-2091.
[9]	YANG Xu, FAN Jieting, SONG Hongyan, FENG Panpan, HAO Jingyu, YAO Mi. Risk Assessment and Communication Strategies for Cardiovascular Diseases in Primary Care [J]. Chinese General Practice, 2026, 29(10): 1294-1299.
[10]	PEI Zhiyi, ZHANG Xiaoxin, LIN Jiayi, ZHANG Xiangyi, KANG Xiaofeng. Systematic Review of the Quality and Application of Patient Decision Aids in Cardiovascular Disease Based on IPDAS 4.0 Criteria [J]. Chinese General Practice, 2026, 29(07): 945-952.
[11]	WANG Yiheng, XU Xiaoming, XIA Yunlong, XIA Linying, HAN Xue, GUO Yongzhen, LIU Quanchi, YAN Wenjun. Progress in Pharmacotherapy of Heart Failure with Preserved Ejection Fraction [J]. Chinese General Practice, 2026, 29(03): 403-408.
[12]	JIANG Xiaorui, YAN Yuyao, WEI Jingjing, QIAO Lijie, PENG Guangcao, ZHU Mingjun. Systematic Review of Risk Prediction Models for Concurrent Heart Failure with Coronary Heart Disease [J]. Chinese General Practice, 2026, 29(03): 393-402.
[13]	ZHANG Yunqiu, LI Yangxue, LIU Haoyang, CHEN Peixuan, WANG Xingyue, CUI Jingya. Research on Comorbidity Conditions and Comorbidity Patterns in Patients with Premature Coronary Heart Disease [J]. Chinese General Practice, 2026, 29(02): 226-231.
[14]	FAN Zhuanzhuan, LI Wenting, MA Guoliang. Relationship between the Chinese Visceral Adipose Index and Cardiovascular Disease in Postmenopausal Women: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(02): 180-187.
[15]	CHEN Li, XIONG Weihong, LU Xiaoqin. Study on Medication Compliance and Influencing Factors in Patients after Percutaneous Coronary Intervention [J]. Chinese General Practice, 2025, 28(36): 4586-4591.